Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of erlotinib in treating patients who have liver
cancer that cannot be surgically removed. Erlotinib may stop the growth of tumor cells by
blocking the enzymes necessary for their growth